메뉴 건너뛰기




Volumn 44, Issue 5, 2009, Pages 470-475

Meta-analysis: The effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

Author keywords

Hepatitis B e antigen; Prognosis; Seroconversion

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; HEPATITIS B(E) ANTIGEN;

EID: 67349226853     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0024-z     Document Type: Article
Times cited : (55)

References (47)
  • 1
    • 67349208527 scopus 로고    scopus 로고
    • World Health Organization. Hepatitis B 2000. Accessed 24 Nov
    • World Health Organization. Hepatitis B 2000. http://www.who.int/ mediacentre/factsheets/fs204/en/ Accessed 24 Nov 2007.
    • (2007)
  • 2
    • 1642410856 scopus 로고    scopus 로고
    • Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
    • Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107.
    • (2004) J Viral Hepat , vol.11 , pp. 97-107
    • Lavanchy, D.1
  • 3
    • 33748114343 scopus 로고    scopus 로고
    • The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
    • Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529-38.
    • (2006) J Hepatol , vol.45 , pp. 529-538
    • Perz, J.F.1    Armstrong, G.L.2    Farrington, L.A.3    Hutin, Y.J.4    Bell, B.P.5
  • 5
    • 19544391413 scopus 로고    scopus 로고
    • Lamivudine for patients with chronic hepatitis B and advanced liver disease
    • Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-31.
    • (2004) N Engl J Med , vol.351 , pp. 1521-1531
    • Liaw, Y.F.1    Sung, J.J.2    Chow, W.C.3    Farrell, G.4    Lee, C.Z.5    Yuen, H.6
  • 6
    • 24344478565 scopus 로고    scopus 로고
    • Molecular virology and the development of resistant mutants: Implications for therapy
    • Locarnini S. Molecular virology and the development of resistant mutants: Implications for therapy. Semin Liver Dis. 2005;25(Suppl 1):9-19.
    • (2005) Semin Liver Dis. , vol.25 , Issue.SUPPL. 1 , pp. 9-19
    • Locarnini, S.1
  • 7
    • 3242683269 scopus 로고    scopus 로고
    • Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B
    • Lin SM, Tai DI, Chien RN, Sheen IS, Chu CM, Liaw YF. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat. 2004;11:349-57.
    • (2004) J Viral Hepat , vol.11 , pp. 349-357
    • Lin, S.M.1    Tai, D.I.2    Chien, R.N.3    Sheen, I.S.4    Chu, C.M.5    Liaw, Y.F.6
  • 8
    • 0033027690 scopus 로고    scopus 로고
    • Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
    • Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971-5.
    • (1999) Hepatology , vol.29 , pp. 971-975
    • Lin, S.M.1    Sheen, I.S.2    Chien, R.N.3    Chu, C.M.4    Liaw, Y.F.5
  • 9
    • 0035061788 scopus 로고    scopus 로고
    • Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach
    • Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol. 2001;34:593-602.
    • (2001) J Hepatol , vol.34 , pp. 593-602
    • Cammà, C.1    Giunta, M.2    Andreone, P.3    Craxì, A.4
  • 10
    • 19944428400 scopus 로고    scopus 로고
    • Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival
    • Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105-14.
    • (2005) Ann Intern Med , vol.142 , pp. 105-114
    • Shiratori, Y.1    Ito, Y.2    Yokosuka, O.3    Imazeki, F.4    Nakata, R.5    Tanaka, N.6
  • 11
    • 33751514752 scopus 로고    scopus 로고
    • Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma
    • Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46:45-52.
    • (2007) J Hepatol , vol.46 , pp. 45-52
    • Lin, S.M.1    Yu, M.L.2    Lee, C.M.3    Chien, R.N.4    Sheen, I.S.5    Chu, C.M.6
  • 13
    • 0035110693 scopus 로고    scopus 로고
    • The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B
    • Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001;34:306-13.
    • (2001) J Hepatol , vol.34 , pp. 306-313
    • Papatheodoridis, G.V.1    Manesis, E.2    Hadziyannis, S.J.3
  • 14
    • 20144388156 scopus 로고    scopus 로고
    • Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma
    • Mahmood S, Niiyama G, Kamei A, Izumi A, Nakata K, Ikeda H, et al. Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int. 2005;25:220-5.
    • (2005) Liver Int. , vol.25 , pp. 220-225
    • Mahmood, S.1    Niiyama, G.2    Kamei, A.3    Izumi, A.4    Nakata, K.5    Ikeda, H.6
  • 16
    • 0028659004 scopus 로고
    • Operating characteristics of a rank correlation test for publication bias
    • Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
    • (1994) Biometrics , vol.50 , pp. 1088-1101
    • Begg, C.B.1    Mazumdar, M.2
  • 17
    • 0032032927 scopus 로고    scopus 로고
    • Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study
    • Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study. Cancer. 1998;82:827-35.
    • (1998) Cancer , vol.82 , pp. 827-835
    • Ikeda, K.1    Saitoh, S.2    Suzuki, Y.3    Kobayashi, M.4    Tsubota, A.5    Fukuda, M.6
  • 18
  • 19
    • 0033179742 scopus 로고    scopus 로고
    • Long-term results with interferon therapy in chronic type B hepatitis: A prospective randomized trial
    • Mazzella G, Saracco G, Festi D, Rosina F, Marchetto S, Jaboli F, et al. Long-term results with interferon therapy in chronic type B hepatitis: A prospective randomized trial. Am J Gastroenterol. 1999;94:2246-50.
    • (1999) Am J Gastroenterol , vol.94 , pp. 2246-2250
    • Mazzella, G.1    Saracco, G.2    Festi, D.3    Rosina, F.4    Marchetto, S.5    Jaboli, F.6
  • 21
    • 0032560376 scopus 로고    scopus 로고
    • Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
    • International Interferon-alpha Hepatocellular Carcinoma Study Group
    • International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet. 1998;351:1535-9.
    • (1998) Lancet , vol.351 , pp. 1535-1539
  • 22
    • 34347234518 scopus 로고    scopus 로고
    • Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients
    • Lu HY, Zhuang LW, Yu YY, Ivan H, Si CW, Zeng Z, et al. Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol. 2007;13:2878-82.
    • (2007) World J Gastroenterol , vol.13 , pp. 2878-2882
    • Lu, H.Y.1    Zhuang, L.W.2    Yu, Y.Y.3    Ivan, H.4    Si, C.W.5    Zeng, Z.6
  • 23
    • 0027378724 scopus 로고
    • Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
    • Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119:312-23.
    • (1993) Ann Intern Med. , vol.119 , pp. 312-323
    • Wong, D.K.1    Cheung, A.M.2    O'Rourke, K.3    Naylor, C.D.4    Detsky, A.S.5    Heathcote, J.6
  • 24
    • 0027313416 scopus 로고
    • Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature
    • Tinè F, Liberati A, Craxì A, Almasio P, Pagliaro L. Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature. J Hepatol. 1993;18:154-62.
    • (1993) J Hepatol , vol.18 , pp. 154-162
    • Tinè, F.1    Liberati, A.2    Craxì, A.3    Almasio, P.4    Pagliaro, L.5
  • 25
    • 0141637207 scopus 로고    scopus 로고
    • Interferon-alpha for HBeAg-positive chronic hepatitis B
    • Craxì A, Di Bona D, Cammà C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol. 2003;39(Suppl 1):S99-105.
    • (2003) J Hepatol , vol.39 , Issue.SUPPL. 1
    • Craxì, A.1    Di Bona, D.2    Cammà, C.3
  • 28
    • 34548806374 scopus 로고    scopus 로고
    • Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients
    • Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology. 2007;46:690-8.
    • (2007) Hepatology , vol.46 , pp. 690-698
    • Hui, C.K.1    Leung, N.2    Shek, T.W.3    Yao, H.4    Lee, W.K.5    Lai, J.Y.6
  • 29
    • 0038045171 scopus 로고    scopus 로고
    • Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
    • Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003;10:298-305.
    • (2003) J Viral Hepat , vol.10 , pp. 298-305
    • Cooksley, W.G.1    Piratvisuth, T.2    Lee, S.D.3    Mahachai, V.4    Chao, Y.C.5    Tanwandee, T.6
  • 30
    • 33846938792 scopus 로고    scopus 로고
    • Genotype B and younger patient age associated with better response to low-dose therapy: A trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China
    • Zhao H, Kurbanov F, Wan MB, Yin YK, Niu JQ, Hou JL, et al. Genotype B and younger patient age associated with better response to low-dose therapy: A trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis. 2007;44:541-8.
    • (2007) Clin Infect Dis. , vol.44 , pp. 541-548
    • Zhao, H.1    Kurbanov, F.2    Wan, M.B.3    Yin, Y.K.4    Niu, J.Q.5    Hou, J.L.6
  • 31
    • 21244447705 scopus 로고    scopus 로고
    • Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    • Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682-95.
    • (2005) N Engl J Med. , vol.352 , pp. 2682-2695
    • Lau, G.K.1    Piratvisuth, T.2    Luo, K.X.3    Marcellin, P.4    Thongsawat, S.5    Cooksley, G.6
  • 32
    • 30344457555 scopus 로고    scopus 로고
    • A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B
    • Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006;166:49-56.
    • (2006) Arch Intern Med , vol.166 , pp. 49-56
    • Lim, S.G.1    Ng, T.M.2    Kung, N.3    Krastev, Z.4    Volfova, M.5    Husa, P.6
  • 33
    • 0037468421 scopus 로고    scopus 로고
    • Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    • Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-16.
    • (2003) N Engl J Med. , vol.348 , pp. 808-816
    • Marcellin, P.1    Chang, T.T.2    Lim, S.G.3    Tong, M.J.4    Sievert, W.5    Shiffman, M.L.6
  • 35
    • 0032499913 scopus 로고    scopus 로고
    • A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
    • Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-8.
    • (1998) N Engl J Med. , vol.339 , pp. 61-68
    • Lai, C.L.1    Chien, R.N.2    Leung, N.W.3    Chang, T.T.4    Guan, R.5    Tai, D.I.6
  • 36
    • 33750499091 scopus 로고    scopus 로고
    • Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine
    • Flink HJ, Hansen BE, Heathcote EJ, Feinman SV, Simsek H, Karayalcin S, et al. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol. 2006;101:2523-9.
    • (2006) Am J Gastroenterol , vol.101 , pp. 2523-2529
    • Flink, H.J.1    Hansen, B.E.2    Heathcote, E.J.3    Feinman, S.V.4    Simsek, H.5    Karayalcin, S.6
  • 37
    • 34548311958 scopus 로고    scopus 로고
    • Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis
    • Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology. 2007;46:388-94.
    • (2007) Hepatology , vol.46 , pp. 388-394
    • Buster, E.H.1    Hansen, B.E.2    Buti, M.3    Delwaide, J.4    Niederau, C.5    Michielsen, P.P.6
  • 38
    • 14844321911 scopus 로고    scopus 로고
    • Hepatitis B virus: Significance of genotypes
    • Schaefer S. Hepatitis B virus: Significance of genotypes. J Viral Hepat. 2005;12:111-24.
    • (2005) J Viral Hepat , vol.12 , pp. 111-124
    • Schaefer, S.1
  • 39
    • 4644219526 scopus 로고    scopus 로고
    • Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma
    • Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut. 2004;53:1494-8.
    • (2004) Gut , vol.53 , pp. 1494-1498
    • Chan, H.L.1    Hui, A.Y.2    Wong, M.L.3    Tse, A.M.4    Hung, L.C.5    Wong, V.W.6
  • 40
    • 0036896130 scopus 로고    scopus 로고
    • HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C
    • Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology. 2002;36:1425-30.
    • (2002) Hepatology , vol.36 , pp. 1425-1430
    • Wai, C.T.1    Chu, C.J.2    Hussain, M.3    Lok, A.S.4
  • 41
    • 34347327007 scopus 로고    scopus 로고
    • Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance
    • Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, Sablon E, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol. 2007;79:1055-63.
    • (2007) J Med Virol , vol.79 , pp. 1055-1063
    • Hou, J.1    Schilling, R.2    Janssen, H.L.3    Hansen, B.E.4    Heijtink, R.5    Sablon, E.6
  • 42
    • 34247538953 scopus 로고    scopus 로고
    • Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
    • Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007;56:699-705.
    • (2007) Gut , vol.56 , pp. 699-705
    • Bonino, F.1    Marcellin, P.2    Lau, G.K.3    Hadziyannis, S.4    Jin, R.5    Piratvisuth, T.6
  • 43
    • 33644882231 scopus 로고    scopus 로고
    • Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype
    • Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL, et al. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006;101:297-303.
    • (2006) Am J Gastroenterol , vol.101 , pp. 297-303
    • Flink, H.J.1    van Zonneveld, M.2    Hansen, B.E.3    de Man, R.A.4    Schalm, S.W.5    Janssen, H.L.6
  • 44
    • 4544239807 scopus 로고    scopus 로고
    • Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    • Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206-17.
    • (2004) N Engl J Med. , vol.351 , pp. 1206-1217
    • Marcellin, P.1    Lau, G.K.2    Bonino, F.3    Farci, P.4    Hadziyannis, S.5    Jin, R.6
  • 45
    • 29944436855 scopus 로고    scopus 로고
    • Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    • Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
    • (2006) JAMA , vol.295 , pp. 65-73
    • Chen, C.J.1    Yang, H.I.2    Su, J.3    Jen, C.L.4    You, S.L.5    Lu, S.N.6
  • 46
    • 13844322073 scopus 로고    scopus 로고
    • Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men
    • Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst. 2005;97:265-72.
    • (2005) J Natl Cancer Inst. , vol.97 , pp. 265-272
    • Yu, M.W.1    Yeh, S.H.2    Chen, P.J.3    Liaw, Y.F.4    Lin, C.L.5    Liu, C.J.6
  • 47
    • 0036614299 scopus 로고    scopus 로고
    • Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
    • Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522-7.
    • (2002) Hepatology , vol.35 , pp. 1522-1527
    • Hsu, Y.S.1    Chien, R.N.2    Yeh, C.T.3    Sheen, I.S.4    Chiou, H.Y.5    Chu, C.M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.